With Alzheimer’s disease therapies finally reaching the market and hundreds of active clinical trials for therapies and diagnostics, it seems like every week brings another potential avenue to explore ...

Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...

Ying Lin, Jacob M. Wozniak, Neil J. Grimsey, Sravan Girada, Anand Patwardhan, Olivia Molinar-Inglis, Thomas H. Smith, John D. Lapek, David J. Gonzalez, JoAnn Trejo Proceedings of the National Academy ...

The story of Q32 Bio, a company that develops therapeutics for inflammatory and autoimmune diseases, started two decades ago. That's when V. Michael Holers, MD, a University of Colorado School of ...

Immunoglobulin A (IgA) nephropathy is the most prevalent glomerulonephritis worldwide that does not have a specific treatment. Its pathogenesis is complex and not well understood, but there is ...

Harvard Medical School scientists have identified a key protein in the human immune system that drives inflammatory and autoimmune conditions when it turns against the body. The protein, Granzyme K, ...

Medically reviewed by Matthew Wosnitzer, MD Complement 3 glomerulopathy (C3G) is a rare kidney disease that is also ...

AJMC ®: How has treatment of complement-driven diseases changed since 2007, when the first complement inhibitor, eculizumab, was approved? SMITH: The development of eculizumab followed our ...

These findings suggest complement protein levels may be an important biomarker for type 1 diabetes. Disruption of the complement system appears to precede the onset of islet autoimmunity (IA), making ...